Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SterisSTE -1.27%86 Debt-to-EBITDA is 1.18 as of Mar. 2026, which is 48% below its 10-year median of 2.29. GuruFocus rates STE with a GF Score™ of 86/100 and a GF Value™ of $270.14 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 467 Medical Devices & Instruments companies, Steris ranks better than 53.96% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Steris's Debt-to-EBITDA or its related term are showing as below:
STE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.31 Med: 2.29 Max: 3.54
Current: 1.31
During the past 13 years, the highest Debt-to-EBITDA Ratio of Steris was 3.54. The lowest was 1.31. And the median was 2.29.
STE's Debt-to-EBITDA is ranked better than 53.96% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs STE: 1.31
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Steris Debt-to-EBITDA Related Terms
Steris Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Steris's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Steris's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Steris's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Steris (STE) has a Debt-to-EBITDA of 1.18 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Steris. This is 48% below median its historical median of 2.29. Over the past decade, Steris' Debt-to-EBITDA has ranged from 1.31 to 3.54. According to the industry distribution chart, Steris ranks #215 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 46%.
Is Steris' Debt-to-EBITDA too high?
Steris' current Debt-to-EBITDA of 1.18 is 48% below median its 10-year median of 2.29. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 3.54. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Steris' value of 1.18 is 24.8% below this industry median. Based on the distribution chart, Steris ranks #215 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Steris has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Steris' Debt-to-EBITDA compare to ZBH and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #215 out of 467 companies for Debt-to-EBITDA. This puts Steris in the upper half of its industry. The industry median Debt-to-EBITDA is 1.57. Steris' value of 1.18 is 24.8% below this benchmark. Historically, Steris' own Debt-to-EBITDA has ranged from 1.31 to 3.54 over the past decade. While the company's 10-year median is 2.29 vs. the industry median of 1.57, Steris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current Debt-to-EBITDA of 1.18 is 24.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Steris. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current Debt-to-EBITDA is 1.18, which is 48% below median its own 10-year median of 2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Based on GuruFocus' analysis, Steris (STE) is currently considered Modestly Undervalued. The stock's GF Value™ is $270.14, compared to a current price of $211.75 — trading 21.6% below its estimated fair value. The current Debt-to-EBITDA is 1.18, which is 48% below median its 10-year median of 2.29 and 24.8% below the Medical Devices & Instruments industry median of 1.57. Steris' overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Steris (STE), the current Debt-to-EBITDA is 1.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (STE) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of $211.75 is trading 21.6% below its estimated GF Value™ of $270.14.
GuruFocus considers Steris to be Modestly Undervalued.
Key valuation signals for STE:
Debt-to-EBITDA: 1.18 (48% below median its 10-year median of 2.29)
GF Value™: $270.14 vs. price of $211.75 (21.6% below fair value)
Industry Position: 24.8% below the Medical Devices & Instruments median (#215 of 467)
No single metric tells the full story. See the STE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
86GF Score
Get the complete analysis for STE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STE has been successfully added to your 
